Related Experiment Video
Updated: Jan 26, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate
Jasmina Makarević1, Jochen Rutz2, Eva Juengel3
1Department of Urology, Goethe-University, D-60590 Frankfurt am Main, Germany. jmakarevic@air-net.de.
Abstract:
The mechanistic target of rapamycin (mTOR) is elevated in prostate cancer, making this protein attractive for tumor treatment. Unfortunately, resistance towards mTOR inhibitors develops and the tumor becomes reactivated. We determined whether epigenetic modulation by the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), may counteract non-responsiveness to the mTOR inhibitor, temsirolimus, in prostate cancer (PCa) cells. Prostate cancer cells, sensitive (parental) and resistant to temsirolimus, were exposed to VPA, and tumor cell growth behavior compared. Temsirolimus resistance enhanced the number of tumor cells in the G2/M-phase, correlating with elevated cell proliferation and clonal growth. The cell cycling proteins cdk1 and cyclin B, along with Akt-mTOR signaling increased, whereas p19, p21 and p27 decreased, compared to the parental cells. VPA significantly reduced cell growth and up-regulated the acetylated histones H3 and H4. Cdk1 and cyclin B decreased, as did phosphorylated mTOR and the mTOR sub-complex Raptor. The mTOR sub-member Rictor and phosphorylated Akt increased under VPA. Knockdown of cdk1, cyclin B, or Raptor led to significant cell growth reduction. HDAC inhibition through VPA counteracts temsirolimus resistance, probably by down-regulating cdk1, cyclin B and Raptor. Enhanced Rictor and Akt, however, may represent an undesired feedback loop, which should be considered when designing future therapeutic regimens.
Insights
Valproic acid (VPA), a histone deacetylase inhibitor, counteracts resistance to temsirolimus, an mTOR inhibitor, in prostate cancer cells. VPA reduces tumor cell growth by down-regulating key cell cycle proteins and mTOR signaling pathways.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Mechanistic target of rapamycin (mTOR) is elevated in prostate cancer (PCa), presenting a therapeutic target.
- Resistance to mTOR inhibitors like temsirolimus is a significant clinical challenge in PCa treatment.
- Epigenetic modifications, such as histone acetylation, play a role in cancer progression and drug resistance.
Purpose of the Study:
- To investigate if valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, can overcome temsirolimus resistance in PCa cells.
- To elucidate the molecular mechanisms by which VPA affects cell cycle progression and signaling pathways in resistant PCa cells.
Main Methods:
- Prostate cancer cell lines, both sensitive and resistant to temsirolimus, were treated with VPA.
- Cell proliferation, clonal growth, and cell cycle distribution were analyzed.
- Expression and activity of key cell cycle proteins (cdk1, cyclin B, p19, p21, p27) and signaling molecules (Akt, mTOR, Raptor, Rictor) were assessed.
- Histone acetylation levels were measured.
- Gene knockdown of specific proteins was performed to assess their role in VPA's effects.
Main Results:
- Temsirolimus-resistant PCa cells exhibited increased G2/M phase population, proliferation, and clonal growth.
- VPA treatment significantly reduced cell growth in resistant PCa cells and increased histone H3 and H4 acetylation.
- VPA decreased cdk1, cyclin B, phosphorylated mTOR, and Raptor levels.
- VPA increased Rictor and phosphorylated Akt levels.
- Knockdown of cdk1, cyclin B, or Raptor mimicked the growth-inhibitory effects of VPA.
Conclusions:
- HDAC inhibition by VPA effectively counteracts temsirolimus resistance in PCa cells, likely through down-regulation of cdk1, cyclin B, and Raptor.
- The observed increase in Rictor and Akt upon VPA treatment may indicate an adaptive feedback loop that warrants consideration in therapeutic strategy design.
More Related Videos
Related Concept Videos
Cells Coordinate Growth and Proliferation
Factors Influencing Microbial Growth: pH
Factors Influencing Microbial Growth: Temperature
Factors Influencing Microbial Growth: Osmolarity
Treatment Resistant Cancers
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

